Biocon, Alkem Labs surge on US FDA nods to products

Representative image.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of pharmaceutical majors Biocon and Alkem Labs surged over 3 percent intraday on Wednesday on approvals by the US drug regulator.

Biocon surged after Mylan received a nod from the US Food and Drug Administration (FDA) for Exemestane tablets, which are used to treat breast cancer.

Meanwhile, Alkem Labs received the nod from the regulator for Lidocaine ointment, which is to treat ventricular tachycardia.

The stock has risen over 5 percent in the past one month. At 10:40 hrs, the stock was quoting at Rs 1,970.00, up Rs 39.15, or 2.03 percent on the BSE. It touched an intraday high of Rs 1,998.25 and an intraday low of Rs 1,952.00.

Biocon, meanwhile, has gained nearly 4 percent in the past one month. At 10:41 hrs, it was quoting at Rs 1,114.00, up Rs 23.20, or 2.13 percent on the BSE. It touched an intraday high of Rs 1,124.90 and an intraday low of Rs 1,107.55.